You are here

  • Home
  • Archive
  • Volume 12, Issue 3
  • Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Outcomes in histopathologic subgroups from the randomized, double-blind, phase 3 KEYNOTE-716 trial

Article metrics

Article menu
Clinical/translational cancer immunotherapy
Original research
Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Outcomes in histopathologic subgroups from the randomized, double-blind, phase 3 KEYNOTE-716 trial

 

Online download statistics by month:

Online download statistics by month: March 2024 to July 2025

AbstractFullPdf
Mar 2024876881402
Apr 2024685696289
May 2024300312160
Jun 2024254260133
Jul 2024215217116
Aug 202418518479
Sep 202415415697
Oct 2024166167103
Nov 202416016186
Dec 202415716069
Jan 202518719093
Feb 2025256256104
Mar 2025145145106
Apr 2025177177104
May 202512012073
Jun 2025909070
Jul 2025220
Total412941742084